Skip to main content

Sullivan Christopher Ryan's Form 4 filing

Avalo Therapeutics, Inc. (AVTX) · filed May 7, 2026

Accession no.
0001810417-26-000010
Filed
May 7, 2026
Trade date
May 6, 2026
Filing delay
1 day
Rule 10b5-1 plan
Checked

This filing lists 6 non-derivative transactions and 1 derivative transaction. Open-market sales total $948.6K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Sullivan Christopher RyanCIK 0001810417Officer (Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 6, 2026Common StockMOption exerciseAcquired+47,000$8.04+$377,88047,423Direct
May 6, 2026Common StockSSaleDisposed−13,834$18.55F2−$256,620.733,589Direct
May 6, 2026Common StockSSaleDisposed−12,347$19.28F3−$238,050.1621,242Direct
May 6, 2026Common StockSSaleDisposed−2,700$20.76F4−$56,05218,542Direct
May 6, 2026Common StockSSaleDisposed−9,219$21.37F5−$197,010.039,323Direct
May 6, 2026Common StockSSaleDisposed−8,900$22.57F6−$200,873423Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
May 6, 2026Common StockMOption exerciseDisposed−47,000$0.00$0116,000Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The reported securities were sold in multiple transactions at prices ranging from $17.95 to $18.90. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Referenced by the price of 1 transaction in Table I.

F3

The reported securities were sold in multiple transactions at prices ranging from $19.02 to $19.91. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Referenced by the price of 1 transaction in Table I.

F4

The reported securities were sold in multiple transactions at prices ranging from $20.04 to $20.81. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Referenced by the price of 1 transaction in Table I.

F5

The reported securities were sold in multiple transactions at prices ranging from $21.10 to $21.90. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Referenced by the price of 1 transaction in Table I.

F6

The reported securities were sold in multiple transactions at prices ranging from $22.26 to $22.88. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)